NAMUR, Belgium, June 14, 2016 /PRNewswire/ -- VolitionRx Limited (NYSE MKT: VNRX),
VolitionRx's proprietary NuQ® blood tests are based on biomarker assays that can identify fragments of chromosomes, called nucleosomes, circulating in the blood and analyze them for epigenetic modifications that signal that cancer is present.
The study, led by VolitionRx lead scientist Dr. Marielle Herzog working with the Department of Surgical Gastroenterology, Hvidovre Hospital, University of Copenhagen, Denmark and the Institute of Clinical Medicine, University of Copenhagen, Denmark evaluated sampling and handling factors of the blood draw and storage process of the NuQ® tests that can impact the tests' stability and fragility. For accurate results in any blood test, it is important to confirm that the results of the test are the same regardless of when and how the blood sample is taken.
VolitionRx Chief Scientific Officer Dr. Jake Micallef commented, "The findings of this study are very good news for us, especially as we head to market in the EU, as no nucleosome stability or fragility issues were found and no special blood draw requirements were needed. What this means for patients is that our NuQ® test will be relatively easy to complete, with no need to fast or limit testing to a specific time of day. The test will also be easy, convenient and cost-effective for both the doctor and the lab since it can be done during a regular blood draw with no special collection, separation, handling or storage requirements."
The study investigated the influence of the following six elements which could affect cfnucleosome blood test stability and/or fragility:
The study concluded that the levels of circulating cfnucleosomes appear stable in most pre-analytical settings, including the processes of sampling and handling blood samples at room temperature prior to centrifugation.
VolitionRx Chief Executive Officer Cameron Reynolds, added, "The validation of our stability study with the publication of this article represents yet another important step toward providing an accurate and easy to use NuQ® diagnostic blood tests to physicians and their patients for the early detection of cancer. This result is key to making our tests low cost and easy to use, as eating, time of day and time of month of sample collection had no meaningful difference in the results for an individual person's biomarker result."
Results from clinical trials demonstrating the effectiveness of VolitionRx's NuQ® biomarker assays include:
Colorectal cancer and pre-cancerous colorectal adenomas
Idiopathic Pulmonary Fibrosis
VolitionRx is a life sciences company focused on developing diagnostic tests for cancer and other conditions. The tests are based on the science of Nucleosomics®, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid – an indication that disease is present.
VolitionRx's goal is to make the tests as common and simple to use, for both patients and doctors, as existing diabetic and cholesterol blood tests. VolitionRx's research and development activities are currently centered in Belgium as the company focuses on bringing its diagnostic products to market first in Europe, then in the U.S. and ultimately, worldwide.
Visit VolitionRx's website (http://www.volitionrx.com) or connect with us via Twitter, LinkedIn, Facebook or YouTube.
Louise Day, [email protected] +44 (0) 7557 774620
Kirsten Thomas, The Ruth [email protected] +1 (508) 280-6592
Scott Powell, VolitionRx [email protected]+1 (646) 650-1351
Lee Roth, The Ruth [email protected] +1 (646) 536-7012
Safe Harbor Statement
Statements in this press release may be "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. Words such as "expects," "anticipates," "intends," "plans," "aims," "targets," "believes," "seeks," "estimates," "optimizing," "potential," "goal," "suggests," "could," "would," "should," "may," "will" and similar expressions identify forward-looking statements. These forward-looking statements relate to the effectiveness of the Company's bodily-fluid-based diagnostic tests as well as the Company's ability to develop and successfully commercialize such test platforms for early detection of cancer. The Company's actual results may differ materially from those indicated in these forward-looking statements due to numerous risks and uncertainties. For instance, if we fail to develop and commercialize diagnostic products, we may be unable to execute our plan of operations. Other risks and uncertainties include the Company's failure to obtain necessary regulatory clearances or approvals to distribute and market future products in the clinical IVD market; a failure by the marketplace to accept the products in the Company's development pipeline or any other diagnostic products the Company might develop; the Company will face fierce competition and the Company's intended products may become obsolete due to the highly competitive nature of the diagnostics market and its rapid technological change; and other risks identified in the Company's most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as other documents that the Company files with the Securities and Exchange Commission. These statements are based on current expectations, estimates and projections about the Company's business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Forward-looking statements are made as of the date of this release, and, except as required by law, the Company does not undertake an obligation to update its forward-looking statements to reflect future events or circumstances.
Nucleosomics®, NuQ® and HyperGenomics® and their respective logos are trademarks and/or service marks of VolitionRx Limited and its subsidiaries. All other trademarks, service marks and trade names referred to in this press release are the property of their respective owners.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/volitionrx-publishes-study-confirming-stability-of-circulating-cell-free-nucleosomes-as-biomarkers-for-cancer-diagnostic-blood-tests-300284212.html
SOURCE VolitionRx Ltd
Subscribe to our Free Newsletters!
Parkinson's disease (PD) is a chronic and progressive disease of the nervous system, causing ...
Iridectomy is a procedure in which an opening is made in the iris of the eye.
Hand hygiene is a simple and affordable technique to prevent infections.View All